title: Once-daily antiretroviral therapy: Spanish Consensus Statement.
abstract: BACKGROUND
  Administration of antiretroviral therapy (ART) once daily is creating extraordinary interest among the members of the scientific community and also among those who receive the therapy. However, in clinical practice, some doubts remain about its use.
  
  
  OBJECTIVE
  This document examines the characteristics and possibilities of treatment administered once daily.
  
  
  METHODS
  Consensus of 248 Spanish experts in the field.
  
  
  RESULTS
  Once-daily dosing is considered an added value which could favour adherence and, therefore, efficacy, as well as the quality of life of certain patients, however, the objective of adequate adherence in the long term is often difficult to achieve regardless of the treatment used. In theory, any patient can receive once-daily therapy, although some patients could particularly benefit from it, e.g. those with unfavourable social or personal circumstances, including drug users, patients whose treatment must be supervised, patients receiving multiple medications, or those who need rescue therapy after multiple treatment failures. At present, it is possible to design once-daily ART using some of the combinations of drugs considered as first-choice in national and international recommendations for antiretroviral therapy, but the options are still limited. The marketing of new drugs with this characteristic could allow us to increase the number and types of patient who can benefit from once-daily regimens, including those patients who need rescue therapy.
  
  
  CONCLUSIONS
  Once-daily ART is a good alternative to regimens administered several times each day when a potent combination of active drugs is available.
authors.affiliation: Hospital Universitario 12 de Octubre, 28041 Madrid, Spain. fpulido@ya.com
authors.forename: F
authors.initials: F
authors.lastname: Pulido
authors.forename: E
authors.initials: E
authors.lastname: Ribera
authors.forename: S
authors.initials: S
authors.lastname: Moreno
authors.forename: A
authors.initials: A
authors.lastname: Muñoz
authors.forename: D
authors.initials: D
authors.lastname: Podzamczer
authors.forename: M A
authors.initials: MA
authors.lastname: del Pozo
authors.forename: A
authors.initials: A
authors.lastname: Rivero
authors.forename: F
authors.initials: F
authors.lastname: Rodríguez
authors.forename: I
authors.initials: I
authors.lastname: Sanjoaquín
authors.forename: R
authors.initials: R
authors.lastname: Teira
authors.forename: P
authors.initials: P
authors.lastname: Viciana
authors.forename: C
authors.initials: C
authors.lastname: Villalonga
authors.forename: A
authors.initials: A
authors.lastname: Antela
authors.forename: J
authors.initials: J
authors.lastname: Carmena
authors.forename: J
authors.initials: J
authors.lastname: Ena
authors.forename: E
authors.initials: E
authors.lastname: Gonzalez
authors.forename: J M
authors.initials: JM
authors.lastname: Kindelán
authors.forename: J
authors.initials: J
authors.lastname: Mallolas
authors.forename: M
authors.initials: M
authors.lastname: Márquez
authors.forename: E
authors.initials: E
authors.lastname: Martínez
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage*; D023241:Antiretroviral Therapy, Highly Active; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D013030:Spain
chemical_list: D019380:Anti-HIV Agents